Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.
FI: 4,38
Type: Article
Collaboration
Year: 2021
Writers
Blancas, I; Olier, C; Count, V; Bayo, JL; Smith, C; Zarcos-Pedrinaci, I; Carabantes, F; Baena-Canada, JM; Cruz, J.; Ruiz-Borrego, M.
Magazine
Title: SCIENTIFIC REPORTS
Quartile
- Q1